{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:20:13Z","timestamp":1789503613472,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T00:00:00Z","timestamp":1532304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejca.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T08:11:03Z","timestamp":1537171863000},"page":"40-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Adjuvant dose-dense doxorubicin-cyclophosphamide\u00a0versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)"],"prefix":"10.1016","volume":"102","author":[{"given":"A.G.J.","family":"van Rossum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"van Werkhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Opdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.A.M.","family":"Mandjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"van Leeuwen \u2013 Stok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"van Tinteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.T.","family":"Imholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.A.","family":"Portielje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.E.M.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van Bochove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Linn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Oosterkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9814","key":"10.1016\/j.ejca.2018.07.013_bib1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Early Breast Cancer Trialists' Collaborative G","year":"2012","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ejca.2018.07.013_bib2","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejca.2018.07.013_bib3","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jnci\/djq409","article-title":"Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"102","author":"Bonilla","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ejca.2018.07.013_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10549-015-3405-4","article-title":"Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials","volume":"151","author":"Petrelli","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2018.07.013_bib5","series-title":"San Antonio Breast Cancer Symposium","author":"Gray","year":"2017"},{"issue":"9","key":"10.1016\/j.ejca.2018.07.013_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/sj.bjc.6603085","article-title":"Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer","volume":"94","author":"Kummel","year":"2006","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.013_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2009.22.1077","article-title":"Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer","volume":"28","author":"Burnell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9472","key":"10.1016\/j.ejca.2018.07.013_bib8","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative G","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejca.2018.07.013_bib9","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1200\/JCO.1990.8.9.1483","volume":"8","author":"Fisher","year":"1990","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2018.07.013_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"issue":"15","key":"10.1016\/j.ejca.2018.07.013_bib11","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J Clin Oncol"},{"issue":"69","key":"10.1016\/j.ejca.2018.07.013_bib12","doi-asserted-by":"crossref","first-page":"113531","DOI":"10.18632\/oncotarget.22697","article-title":"Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy","volume":"8","author":"van Rossum","year":"2017","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.ejca.2018.07.013_bib13","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2013.53.7142","article-title":"Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)","volume":"32","author":"Shulman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.013_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-017-0911-9","article-title":"Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up","volume":"19","author":"Ohnstad","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2018.07.013_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10549-014-3259-1","article-title":"Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial","volume":"149","author":"Liu","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.ejca.2018.07.013_bib16","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s00268-016-3570-6","article-title":"Staging PET-CT scanning provides superior detection of lymph nodes and distant metastases than traditional imaging in locally advanced breast cancer","volume":"40","author":"Garg","year":"2016","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.013_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-011-1767-9","article-title":"18F-FDG PET\/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques","volume":"131","author":"Koolen","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.ejca.2018.07.013_bib18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2018.07.013_bib19","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ncponc0560","article-title":"The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens","volume":"3","author":"Simon","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ejca.2018.07.013_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2016.10.030","article-title":"Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies","volume":"71","author":"Lambertini","year":"2017","journal-title":"Eur J Cancer"},{"issue":"36","key":"10.1016\/j.ejca.2018.07.013_bib21","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial","volume":"24","author":"Roche","year":"2006","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2018.07.013_bib22","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1200\/JCO.2007.14.2471","article-title":"Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression","volume":"26","author":"Anders","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.07.013_bib23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S1470-2045(04)01494-9","article-title":"Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer","volume":"5","author":"Nowak","year":"2004","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.013_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","article-title":"Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial","volume":"14","author":"Mackey","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2018.07.013_bib25","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/annonc\/mdq683","article-title":"Long-term toxic effects of adjuvant chemotherapy in breast cancer","volume":"22","author":"Azim","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.07.013_bib26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3109\/0284186X.2014.969846","article-title":"Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer","volume":"54","author":"Eckhoff","year":"2015","journal-title":"Acta Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:21:55Z","timestamp":1760732515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918309821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":26,"alternative-id":["S0959804918309821"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant dose-dense doxorubicin-cyclophosphamide\u00a0versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}